RU2008145701A - Производные пурина для применения в качестве агонистов аденозинового рецептора a2a - Google Patents
Производные пурина для применения в качестве агонистов аденозинового рецептора a2a Download PDFInfo
- Publication number
- RU2008145701A RU2008145701A RU2008145701/15A RU2008145701A RU2008145701A RU 2008145701 A RU2008145701 A RU 2008145701A RU 2008145701/15 A RU2008145701/15 A RU 2008145701/15A RU 2008145701 A RU2008145701 A RU 2008145701A RU 2008145701 A RU2008145701 A RU 2008145701A
- Authority
- RU
- Russia
- Prior art keywords
- optionally substituted
- alkyl
- amino
- membered heterocyclic
- heterocyclic ring
- Prior art date
Links
- 239000002465 adenosine A2a receptor agonist Substances 0.000 title 1
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 title 1
- 150000003212 purines Chemical class 0.000 title 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims abstract 30
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims abstract 30
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 20
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract 19
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 19
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 19
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 19
- 239000001301 oxygen Chemical group 0.000 claims abstract 19
- 229910052717 sulfur Chemical group 0.000 claims abstract 19
- 239000011593 sulfur Chemical group 0.000 claims abstract 19
- 125000005842 heteroatom Chemical group 0.000 claims abstract 18
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract 18
- 229910052736 halogen Inorganic materials 0.000 claims abstract 13
- 150000002367 halogens Chemical group 0.000 claims abstract 13
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 13
- 239000001257 hydrogen Substances 0.000 claims abstract 13
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract 8
- 150000001875 compounds Chemical class 0.000 claims abstract 8
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims abstract 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 6
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims abstract 5
- 125000003282 alkyl amino group Chemical group 0.000 claims abstract 5
- -1 hydroxy, carboxy, amino Chemical class 0.000 claims abstract 5
- 125000004093 cyano group Chemical class *C#N 0.000 claims abstract 4
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 claims abstract 4
- 125000004043 oxo group Chemical class O=* 0.000 claims abstract 4
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims abstract 3
- 150000003839 salts Chemical group 0.000 claims abstract 2
- 125000003118 aryl group Chemical group 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 102000009346 Adenosine receptors Human genes 0.000 claims 2
- 108050000203 Adenosine receptors Proteins 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000006730 (C2-C5) alkynyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 206010060965 Arterial stenosis Diseases 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 238000011374 additional therapy Methods 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000012216 imaging agent Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000012800 visualization Methods 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- MGGMQKJVDNWTCB-UHFFFAOYSA-N CC(C)[n]1cnc(CCNC)c1 Chemical compound CC(C)[n]1cnc(CCNC)c1 MGGMQKJVDNWTCB-UHFFFAOYSA-N 0.000 description 1
- WPLQOYDOQAASMD-LBPRGKRZSA-N CC(NCCNC(N[C@@H](CC1)CN1c1ncccc1)=O)=O Chemical compound CC(NCCNC(N[C@@H](CC1)CN1c1ncccc1)=O)=O WPLQOYDOQAASMD-LBPRGKRZSA-N 0.000 description 1
- ALOCUZOKRULSAA-UHFFFAOYSA-N CN(CC1)CCC1N Chemical compound CN(CC1)CCC1N ALOCUZOKRULSAA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0607953.7 | 2006-04-21 | ||
| GBGB0607953.7A GB0607953D0 (en) | 2006-04-21 | 2006-04-21 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008145701A true RU2008145701A (ru) | 2010-05-27 |
Family
ID=36581050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008145701/15A RU2008145701A (ru) | 2006-04-21 | 2007-04-19 | Производные пурина для применения в качестве агонистов аденозинового рецептора a2a |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20090105476A1 (enExample) |
| EP (1) | EP2012760A2 (enExample) |
| JP (1) | JP2009534339A (enExample) |
| KR (1) | KR20080110923A (enExample) |
| CN (1) | CN101426483A (enExample) |
| AU (1) | AU2007241344A1 (enExample) |
| BR (1) | BRPI0710655A2 (enExample) |
| CA (1) | CA2648813A1 (enExample) |
| GB (1) | GB0607953D0 (enExample) |
| MX (1) | MX2008013418A (enExample) |
| RU (1) | RU2008145701A (enExample) |
| WO (1) | WO2007121921A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200500281A (es) * | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0500785D0 (en) | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| AR060607A1 (es) | 2006-04-21 | 2008-07-02 | Novartis Ag | Derivados de purina,composiciones farmaceuticas que los contienen, metodo de preparacion y usos en enfermedades obstructivas o inflamatorias de las vias respiratorias. |
| GB0607948D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607945D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607950D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| EP1889846A1 (en) | 2006-07-13 | 2008-02-20 | Novartis AG | Purine derivatives as A2a agonists |
| EP1903044A1 (en) * | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
| KR20090087054A (ko) * | 2006-11-10 | 2009-08-14 | 노파르티스 아게 | 시클로펜텐 디올 모노아세테이트 유도체 |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US20100197914A1 (en) * | 2007-10-17 | 2010-08-05 | Robin Alec Fairhurst | Purine Derivatives as Adenosine Al Receptor Ligands |
| US20090181934A1 (en) * | 2007-10-17 | 2009-07-16 | Novartis Ag | Organic Compounds |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| AU2011336264A1 (en) | 2010-12-03 | 2013-06-20 | Epizyme, Inc. | Carbocycle-substituted purine and 7-deazapurine compounds |
| KR20130124959A (ko) | 2010-12-03 | 2013-11-15 | 에피자임, 인코포레이티드 | 히스톤 메틸전달효소의 7-데아자퓨린 조절제 및 그의 사용방법 |
| BR112013013659B8 (pt) | 2010-12-03 | 2024-02-27 | Epizyme Inc | Compostos moduladores de enzimas epigenéticas, composição farmacêutica compreendendo ditos compostos e usos da dita composição farmacêutica para tratar câncer, câncer hematológico ou leucemia |
| WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
| SI2712358T1 (sl) | 2011-05-13 | 2017-03-31 | Array Biopharma, Inc. | Spojine pirolidinil sečnine, pirolidinil tiosečnine in pirolidinil gvanidina kot inhibitorji kinaze trka |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US20150284422A1 (en) | 2012-08-10 | 2015-10-08 | Epizyme, Inc. | Inhibitors of protein methyltransferase dot1l and methods of use thereof |
| WO2014039839A1 (en) | 2012-09-06 | 2014-03-13 | Epizyme, Inc. | Method of treating leukemia |
| EP2968387A4 (en) | 2013-03-15 | 2017-04-05 | Epizyme, Inc. | Methods of synthesizing substituted purine compounds |
| PT3154959T (pt) | 2014-05-15 | 2019-09-24 | Array Biopharma Inc | 1-((3s,4r)-4-(3-fluorofenil)-1-(2-metoxietil)-pirrolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)ureia como inibidor da cinase trka |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1528382A (en) * | 1974-12-26 | 1978-10-11 | Teijin Ltd | Cyclopentene diols and acyl esters thereof and processes for their preparation |
| US4738954A (en) * | 1985-11-06 | 1988-04-19 | Warner-Lambert Company | Novel N6 -substituted-5'-oxidized adenosine analogs |
| US4954504A (en) * | 1986-11-14 | 1990-09-04 | Ciba-Geigy Corporation | N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity |
| US5688774A (en) * | 1993-07-13 | 1997-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | A3 adenosine receptor agonists |
| KR19990076966A (ko) * | 1996-01-02 | 1999-10-25 | 오엘러 로스 제이. | 2,4-디하이드록시피리딘과 2,4-디하이드록시-3-니트로피리딘의 제조방법 |
| US6376472B1 (en) * | 1996-07-08 | 2002-04-23 | Aventis Pharmaceuticals, Inc. | Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
| GB9813535D0 (en) * | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| GB9813554D0 (en) * | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| DE69920045T2 (de) * | 1998-12-31 | 2005-09-29 | Aventis Pharmaceuticals Inc. | Verfahren zur herstellung von n6-substituierten deaza-adenosinderivaten |
| US7427606B2 (en) * | 1999-02-01 | 2008-09-23 | University Of Virginia Patent Foundation | Method to reduce inflammatory response in transplanted tissue |
| US6586413B2 (en) * | 1999-11-05 | 2003-07-01 | The United States Of America As Represented By The Department Of Health And Human Services | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
| EP1365776B1 (en) * | 2001-01-16 | 2005-04-13 | Can-Fite Biopharma Ltd. | Use of an adenosine a3 receptor agonist for inhibition of viral replication |
| US20040162422A1 (en) * | 2001-03-20 | 2004-08-19 | Adrian Hall | Chemical compounds |
| EP1258247A1 (en) * | 2001-05-14 | 2002-11-20 | Aventis Pharma Deutschland GmbH | Adenosine analogues for the treatment of insulin resistance syndrome and diabetes |
| US7414036B2 (en) * | 2002-01-25 | 2008-08-19 | Muscagen Limited | Compounds useful as A3 adenosine receptor agonists |
| US7465715B2 (en) * | 2003-12-29 | 2008-12-16 | Can-Fite Biopharma, Ltd. | Method for treatment of multiple sclerosis |
| KR20070004792A (ko) * | 2004-03-05 | 2007-01-09 | 캠브리지 바이오테크놀로지 리미티드 | 아데노신 수용체 작용제 |
| US7825102B2 (en) * | 2004-07-28 | 2010-11-02 | Can-Fite Biopharma Ltd. | Treatment of dry eye conditions |
| EP1794162A1 (en) * | 2004-09-09 | 2007-06-13 | The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health | Purine derivatives as a3 and a1 adenosine receptor agonists |
| GT200500281A (es) * | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| US20080051364A1 (en) * | 2004-11-08 | 2008-02-28 | Pninna Fishman | Therapeutic Treatment of Accelerated Bone Resorption |
| GB0500785D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| DK1848718T3 (da) * | 2005-02-04 | 2012-08-27 | Millennium Pharm Inc | E1 aktiveringsenzymhæmmere |
| BRPI0619395A2 (pt) * | 2005-11-30 | 2011-10-04 | Can Fite Biopharma Ltd | uso de um agonista de receptor de adenosina a3(a3ar) |
| KR101383228B1 (ko) * | 2006-01-26 | 2014-04-09 | 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 레프리젠티드 바이 더 세크러터리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비스즈 | Ａ3 아데노신 수용체 알로스테릭 조절제 |
| PT1989206E (pt) * | 2006-02-02 | 2012-10-15 | Millennium Pharm Inc | Inibidores da enzima de ativação e1 |
| GB0607944D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607945D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607948D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607954D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| US8008307B2 (en) * | 2006-08-08 | 2011-08-30 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of E1 activating enzymes |
| EP1903044A1 (en) * | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
| KR20090087054A (ko) * | 2006-11-10 | 2009-08-14 | 노파르티스 아게 | 시클로펜텐 디올 모노아세테이트 유도체 |
| US20090181934A1 (en) * | 2007-10-17 | 2009-07-16 | Novartis Ag | Organic Compounds |
-
2006
- 2006-04-21 GB GBGB0607953.7A patent/GB0607953D0/en not_active Ceased
-
2007
- 2007-04-19 JP JP2009505780A patent/JP2009534339A/ja active Pending
- 2007-04-19 MX MX2008013418A patent/MX2008013418A/es not_active Application Discontinuation
- 2007-04-19 AU AU2007241344A patent/AU2007241344A1/en not_active Abandoned
- 2007-04-19 EP EP07724373A patent/EP2012760A2/en not_active Withdrawn
- 2007-04-19 CA CA002648813A patent/CA2648813A1/en not_active Abandoned
- 2007-04-19 BR BRPI0710655-6A patent/BRPI0710655A2/pt not_active IP Right Cessation
- 2007-04-19 US US12/297,940 patent/US20090105476A1/en not_active Abandoned
- 2007-04-19 KR KR1020087028380A patent/KR20080110923A/ko not_active Withdrawn
- 2007-04-19 WO PCT/EP2007/003436 patent/WO2007121921A2/en not_active Ceased
- 2007-04-19 CN CNA2007800144345A patent/CN101426483A/zh active Pending
- 2007-04-19 RU RU2008145701/15A patent/RU2008145701A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| GB0607953D0 (en) | 2006-05-31 |
| WO2007121921A3 (en) | 2008-01-10 |
| CA2648813A1 (en) | 2007-11-01 |
| JP2009534339A (ja) | 2009-09-24 |
| KR20080110923A (ko) | 2008-12-19 |
| BRPI0710655A2 (pt) | 2011-08-16 |
| EP2012760A2 (en) | 2009-01-14 |
| CN101426483A (zh) | 2009-05-06 |
| MX2008013418A (es) | 2008-11-04 |
| WO2007121921A2 (en) | 2007-11-01 |
| AU2007241344A1 (en) | 2007-11-01 |
| US20090105476A1 (en) | 2009-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008145701A (ru) | Производные пурина для применения в качестве агонистов аденозинового рецептора a2a | |
| RU2008145704A (ru) | Пуриновые производные в качестве агонистов a2a-рецептора | |
| ES2533788T3 (es) | Compuestos inhibidores de PI3K de tipo purina y métodos de uso | |
| ES2969383T3 (es) | Derivados de N-(fenil)-indol-3-sulfonamida y compuestos relacionados como moduladores de GPR17 para el tratamiento de trastornos del SNC tales como la esclerosis múltiple | |
| ES2572980T3 (es) | Combinación de inhibidores de la proteasa del VHC con un tensioactivo | |
| RU2012144317A (ru) | Противоинфекционные соединения | |
| RU2008114378A (ru) | Производные 2-аминопиримидина как модуляторы активности н4-рецептора гистамина | |
| UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
| AR075583A1 (es) | Derivados de isoxazol/o-piridina con eslabon etilo o etenilo | |
| RU2400483C2 (ru) | Пуриновые производные в качестве агонистов рецептора a2a | |
| CL2011002706A1 (es) | Compuestos derivados de 4-(1,3-oxazol-2-il)-1h-indazol; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades tales como epoc, autoinmunes, asma, entre otras. | |
| ES2558608T3 (es) | Derivados hetero-bicíclicos como inhibidores del VHC | |
| AR033678A1 (es) | Derivados de quinolina, procedimiento para prepararlos, uso de los mismos para la preparacion de medicamentos y los medicamentos que contienen dichos derivados | |
| AR078536A1 (es) | Derivados de pirazol como ligandos del receptor de estrogeno | |
| UY31126A1 (es) | Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus | |
| GT200900007A (es) | Derivados de purina como agonistas de a2a | |
| AR036114A1 (es) | Tetrahidroimidazol[1,2-a]pirazinas y tetrahidrotriazol[4,3-a]pirazinas como inhibidores de la dipeptidil peptidasa utiles para el tratamiento o la prevencion de la diabetes | |
| CL2012000708A1 (es) | Compuestos derivados de imidazopiridina o imidazopirimidina, inhibidores de pde10a; proceso de preparacion de dichos compuestos; composiciones farmaceuticas; y su uso para el tratamiento terapeutico y/o preventivo de trastornos psicoticos, esquizofrenia, enfermedad de alzheimer, tumores solidos, entre otras enfermedades. | |
| AR069843A1 (es) | Derivados de piridazinona, procedimiento para preparar dichos compuestos, composiciones farmaceuticas y usos de los mismos para preparar un medicamento | |
| AR077999A1 (es) | Antagonistas de pirimidin y triazin-hepcidina | |
| BR112017002370B1 (pt) | Compostos indóis, composição farmacêutica que os compreende e seu uso na inibição da replicação do vírus da gripe | |
| AR073932A1 (es) | Compuestos de esteres de acido 2-(aminometiliden)-4,4-difluoro-3- oxobutirico y procedimiento para su preparacion | |
| RU2010147918A (ru) | 5-метил-1-(нафталин-2-ил)-1н-пиразолы в качестве ингибиторов сигма-рецепторов | |
| MX2009000675A (es) | Concentrados acuosos de principios activos con efecto herbicida. | |
| ECSP077404A (es) | Derivados de purina para usarse como agonistas de receptores a-2a de adenosina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20100623 |